SELECT PIPELINE DRUG CANDIDATES II-14 Orexigen Completes Phase 3 Clinical Trials for NB32 II-14 Empatic(TM) Completes Phase II II-14 Zafgen Completes Phase II Trial of Beloranib II-14 Novo Nordisk Completes Phase III trial of Liraglutide II-14 Rhythm Pharmaceuticals Commences Phase 2 Trials for RM 493 II-14 University of Michigan to Commence Trial of Amlexanox
in Treating Obesity II-15 5.
Washington, February 11( ANI ): Amlexanox
, an off-patent drug currently prescribed for the treatment of asthma and other uses, also reverses obesity, diabetes and fatty liver in mice, a new study has found.
Summary: TEHRAN (FNA)- Researchers at the University of Michigan's Life Sciences Institute have found that amlexanox
, an off-patent drug currently prescribed for the treatment of asthma and other uses, also reverses obesity, diabetes and fatty liver in mice.
2,4) To date, the most effective, widely studied and cost-effective topical drug on the market is Amlexanox
Meda (STO:MEDAA) has entered into an agreement with Uluru Inc, a US specialty pharma company, for Amlexanox
5% paste and OraDisc A[TM].
1% - 15 gm (3 supply and safe delivery of - tube - amlexanox
5% w/w - 3 gm (4 supply and safe delivery of syp cough syrup containing minimum ingredient in each 5ml of following: terbutaline+ambroxol - 100 ml (5supply and safe delivery of - tab - cetirizine+ ambroxol - 5+60 mg.
Product Partner Territory OraDisc- Benzocaine Wyeth Consumer Healthcare North America OraDisc- Amlexanox
Discus Dental United States Zambon Europe Esteve Spain, Portugal, Greece Meda AB Scandinavia ProStrakan UK Ireland EpiTan Australia / New Zealand Orient Europharma Asia
is a novel anti-inflammatory and anti-allergic agent that has been approved and used in the US, Japan and other countries, in numerous formulations, for the treatment of a variety of conditions including recurrent aphthous ulceration (RAU), bronchial asthma and allergic rhinitis.
The data generated by this study confirms that amlexanox
accelerates the healing of oral wounds.
NYSE Alternext: ULU) today announced the signing of a License Agreement with Meda AB (Meda) to market Amlexanox
5% paste and OraDisc(TM) A throughout the European Union, Eastern Europe and the Commonwealth of Independent States excluding Spain, Portugal and Greece.
Bridge Technology Group LLC announced today that it has reiterated its BUY recommendation on Access Pharmaceuticals (OTC:AXCS) following AXCS' announcement that it had acquired rights from Block Drug Company to amlexanox
for the indication of mucositis.
OTC BB:AXCS) today announced that it has signed a Letter of Intent to license amlexanox
5% paste to Laboratorios Dr.